Dynogen Pharmaceuticals

Dynogen was developing a portfolio of therapies for gastrointestinal and genitourinary disorders. Due to deteriorating market conditions a previously announced purchase by a Special Purpose Acquisition Company was later cancelled and Dynogen was unable to secure further financing after the clinical data in one of its programmes was not sufficiently positive. The company was placed in administration in February 2009.